Compare CGEM & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | HAFC |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 929.0M |
| IPO Year | 2020 | 2000 |
| Metric | CGEM | HAFC |
|---|---|---|
| Price | $18.40 | $32.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | $30.13 | ★ $32.17 |
| AVG Volume (30 Days) | ★ 1.4M | 200.0K |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | N/A | ★ 22.44 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $270,165,000.00 |
| Revenue This Year | N/A | $18.65 |
| Revenue Next Year | $5.20 | $7.28 |
| P/E Ratio | ★ N/A | $43.29 |
| Revenue Growth | N/A | ★ 15.28 |
| 52 Week Low | $5.68 | $22.00 |
| 52 Week High | $18.76 | $32.52 |
| Indicator | CGEM | HAFC |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 63.20 |
| Support Level | $11.87 | $29.04 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.39 | 0.63 |
| MACD | 0.52 | 0.09 |
| Stochastic Oscillator | 82.34 | 78.99 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.